Scholarlink

Background <p>The incidence of pancreatic ductal adenocarcinoma (PDAC) is constantly increasing. Surgical resection, in combination with systemic chemotherapy, offers the only option for long-term survival or even cure. However, the high toxicity rates of modern and most-effective chemotherapy protocols limit this treatment option to patients with good performance status (PS). Consequently, the Eastern Cooperative Oncology Group (ECOG) performance score is essential for selecting treatment protocols. In addition, the perioperative complications and survival rates of patients with a&#xa0;reduced PS undergoing surgery for PDAC are unclear.</p> Objective <p>This study aims to evaluate the perioperative morbidity and mortality rates in patients with a&#xa0;reduced PS (ECOG ≥ 2) after resection of PDAC as well as disease-free (DFS) and overall survival (OS).</p> Methods <p>This is a&#xa0;pan-European and African retrospective study conducted at participating centers represented by members of the European–African Hepato-Pancreato-Biliary Association (E-AHPBA). This study will include all consecutive patients with ECOG PS ≥ 2 who underwent pancreatic surgery for PDAC between January&#xa0;1, 2015, and December&#xa0;31, 2024. Participating centers enter data via an electronic case report form on REDCap® (Vanderbilt University, Tennessee). The primary outcomes are perioperative morbidity and mortality rates, DFS, and OS. The secondary objectives are related to the type of chemotherapy regimens applied.</p> Conclusion <p>Impaired PS may negatively affect surgical and oncological treatment algorithms and outcomes. This multicenter study will help to understand how patients with PDAC and ECOG PS ≥ 2 are treated in daily clinical practice throughout Europe and Africa. The results of this large patient cohort analysis are expected to identify the best treatment algorithm for this patient group.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Outcomes of pancreatic surgery for localized pancreatic adenocarcinoma in patients with impaired ECOG performance status (PANCOG study)—protocol of a retrospective pan-European and African multicenter study

  • 期刊论文

  • 发表日期：

    2026年4月14日

查看全文
  • S. Löb,
  • M. De Oliveira,
  • M. Lesurtel,
  • U. Klaiber,
  • O. Strobel,
  • C. H. J. Van Eijck,
  • M. Besselink,
  • K. Emmanuel,
  • M. Varga

摘要

Background

The incidence of pancreatic ductal adenocarcinoma (PDAC) is constantly increasing. Surgical resection, in combination with systemic chemotherapy, offers the only option for long-term survival or even cure. However, the high toxicity rates of modern and most-effective chemotherapy protocols limit this treatment option to patients with good performance status (PS). Consequently, the Eastern Cooperative Oncology Group (ECOG) performance score is essential for selecting treatment protocols. In addition, the perioperative complications and survival rates of patients with a reduced PS undergoing surgery for PDAC are unclear.

Objective

This study aims to evaluate the perioperative morbidity and mortality rates in patients with a reduced PS (ECOG ≥ 2) after resection of PDAC as well as disease-free (DFS) and overall survival (OS).

Methods

This is a pan-European and African retrospective study conducted at participating centers represented by members of the European–African Hepato-Pancreato-Biliary Association (E-AHPBA). This study will include all consecutive patients with ECOG PS ≥ 2 who underwent pancreatic surgery for PDAC between January 1, 2015, and December 31, 2024. Participating centers enter data via an electronic case report form on REDCap® (Vanderbilt University, Tennessee). The primary outcomes are perioperative morbidity and mortality rates, DFS, and OS. The secondary objectives are related to the type of chemotherapy regimens applied.

Conclusion

Impaired PS may negatively affect surgical and oncological treatment algorithms and outcomes. This multicenter study will help to understand how patients with PDAC and ECOG PS ≥ 2 are treated in daily clinical practice throughout Europe and Africa. The results of this large patient cohort analysis are expected to identify the best treatment algorithm for this patient group.